TRN 157

Drug Profile

TRN 157

Alternative Names: TRN-157

Latest Information Update: 05 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Theron Pharmaceuticals
  • Class Antiasthmatics; Antibronchitics; Bronchodilators
  • Mechanism of Action Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Asthma
  • Phase I Chronic obstructive pulmonary disease

Most Recent Events

  • 05 Sep 2017 TRN 157 is still in phase II trials for Asthma in USA
  • 01 Mar 2016 Theron Pharmaceuticals completes a phase II trial in Asthma in USA (Inhalation) (NCT02382510)
  • 01 Feb 2015 Phase-II clinical trials in Asthma in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top